Effect of Alpha-Lipoic Acid Supplementation on Endothelial Function and Cardiovascular Risk Factors in Overweight/Obese Youths: A Double-Blind, Placebo-Controlled Randomized Trial.

Nutrients. 2019;11(2)
Full text from:

Plain language summary

Children who are obese or overweight are at a higher risk of developing heart disease. Damage to the lining of the blood vessels may be an early indicator of potential heart disease. Alpha-lipoic acid (ALA) is a supplement that has anti-oxidant and anti-inflammatory effects, and has been shown to improve blood vessel function in adults with metabolic diseases, and children with type 1 diabetes. It is not yet known whether ALA supplementation can benefit cardiovascular health in overweight/obese youths. The aim of this double-blind placebo-controlled randomised trial was to investigate whether supplementation with ALA improved endothelial function and risk factors for cardiovascular disease in overweight and obese youths. 64 overweight/obese youths aged 8-16 years old were given either 800mg ALA or a placebo for 12 weeks. All participants were instructed to follow a balanced low-calorie diet and advised to engage in a moderate daily exercise program (60 min/day at least five days a week). At the end of the study, blood vessel function, as assessed by flow-mediated dilation (FMD) of the brachial artery, did not change significantly in either of the groups. However, the basal and peak diameter of the brachial artery significantly increased after ALA treatment, compared to placebo. There were no significant changes between groups or over time for blood pressure, weight or body mass index (BMI), nor were there any significant changes in glucose, insulin or fat levels within the blood. The authors concluded that ALA supplementation improves the tone of blood vessels and may have a beneficial effect on heart health in overweight/obese youths.

Abstract

Endothelial dysfunction is recognized as an early sign of systemic atherosclerosis, and it represents a therapeutic target to prevent long-term cardiovascular (CV) consequences. Alpha-lipoic acid (ALA) is a commonly used dietary supplement exerting anti-oxidant and anti-inflammatory effects. We investigated whether a three-month treatment with ALA improves endothelial function, as assessed by flow-mediated dilation (FMD) of the brachial artery, and clinical and metabolic risk factors in overweight/obese youths. We enrolled 67 overweight/obese children, and 22 normal-weight metabolically healthy controls. Overweight/obese youths were randomly allocated in a double-blinded manner to receive ALA (n = 34) or placebo (n = 33). Of these, 64 (32 ALA, 32 placebo) completed the follow-up. At baseline, in ALA and placebo groups, FMD was similar, but lower as compared with that in controls (p = 0.045). At three months, within the ALA and placebo groups, FMD did not change significantly. However, the basal and peak diameter of brachial artery significantly increased after ALA treatment as compared to placebo (p = 0.036 and p = 0.01, respectively). There were no significant within- and between-group changes for anthropometric and metabolic variables. The results show that ALA supplementation improves vascular tone and may have a beneficial effect on CV health in overweight/obese youths.

Lifestyle medicine

Fundamental Clinical Imbalances : Immune and inflammation ; Structural
Patient Centred Factors : Mediators/Cardiovascular disease
Environmental Inputs : Nutrients
Personal Lifestyle Factors : Nutrition
Functional Laboratory Testing : Blood
Bioactive Substances : Alpha-lipoic acid ; ALA

Methodological quality

Jadad score : 5
Allocation concealment : Yes

Metadata